Matt Angle

Dr. Matt Angle is the founder and CEO of Paradromics, a neurotechnology company specializing in brain-computer interface (BCI) development. Drawing on research conducted at Stanford University, Angle recognized the potential for high-data rate, high-reliability BCIs to expand the possibilities of brain-health applications. He holds a Bachelor of Science from Carnegie Mellon University and a doctorate in neuroscience from the University of Heidelberg, having completed doctoral studies at the Max Planck Institute for Medical Research and postdoctoral work at Stanford University. This academic background provided Angle with a foundation in neuroscience and engineering, supporting his transition from laboratory research to medical device innovation.

Paradromics was established to translate neural recording technology from academic research into a fully implantable, wireless commercial medical device. Early in its development, Paradromics secured funding from the National Institutes of Health Small Business Innovation Research program and the Defense Advanced Research Projects Agency, totaling $15 million. This support facilitated the advancement of its core BCI technology and enabled the company to attract venture capital. Paradromics later raised $33 million in a venture round led by Prime Movers Lab, with participation from Westcott Investment Group, Dolby Family Ventures, and Green Sands Equity. Under Angle's leadership, the company has raised $38 million in venture funding and received $18 million in non-dilutive public funding from DARPA and the NIH.

The central focus of Paradromics is the "Connexus" BCI platform, a high data-rate brain-computer interface featuring a fully implantable system that collects neural data and transmits it wirelessly to an external device. This system translates neural signals into speech or computer inputs in real time. The Connexus BCI received Breakthrough Device Designation from the U.S. Food and Drug Administration, expediting its review as a transformative medical device for individuals with debilitating neurological conditions. A subsequent designation was granted for enabling people with severe motor deficits to control computer devices.

Angle is an advocate for the use of neurotechnology in medicine, emphasizing Paradromics' focus on clinical applications over consumer products. The company develops BCI technology for individuals with ALS, locked-in syndrome, and other motor-speech impairments. Angle's advocacy includes participation in initiatives such as the White House Summit on Biotechnology and Biomanufacturing, which addressed policy and investment in the biotechnology sector.

In addition to leading Paradromics, Angle contributes to the broader neurotechnology field through media and partnerships. He has appeared on Scripps News to discuss advancements in brain-computer interfaces and hosts the "Neurotech Pub" podcast, where he interviews neuroscience experts and industry leaders. Through the APEX Partnership Program, Angle has established collaborations with scientists and clinicians at Stanford University, Massachusetts General Hospital, the University of Pittsburgh, the University of Michigan, and UC Davis, advancing BCI applications for individuals with neurological impairments. His work integrates neuroscience, medical device engineering, and clinical research, positioning him as a key figure in the development of brain-computer interface technology and its role in healthcare.